Sagimet Biosciences is a catalyst-driven biotech, with value anchored to the upcoming U.S. Phase 3 denifanstat acne trial. SGMT's recent $175M equity raise extends cash runway through 2028, de-risking near-term financing and supporting Phase 3 execution. The U.S. Phase 3 trial aims to replicate strong China data, targeting best-in-class oral efficacy and safety in moderate-to-severe acne.